Cellipont Bioservices | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Cellipont Bioservices

Team Bitscale

24 Feb 2026 — 1 min read

Cellipont Bioservices

Overview

Cellipont Bioservices is a cell therapy Contract Development and Manufacturing Organization (CDMO) headquartered in Spring, Texas. Established in 2002 and rebranded in 2022, the company specializes in developing, providing analytical services, and manufacturing cell therapies such as CAR-T, TCR-T, and NK cells. Its 76,000 square foot facility in Houston, inaugurated in March 2024, is designed for process development, assay development, and GMP operations from preclinical stages to commercialization.

Cellipont offers comprehensive support to cell therapy programs, with solutions spanning process development, clinical and commercial manufacturing, and analytical development. The team focuses on translating processes from research to clinical use, prioritizing quality and technology to improve patient access. Collaborations with biotech partners like Optieum Bio and Wugen, Inc. help advance therapies for unmet medical needs.

Basic Information

Industry	research
Founded	2002
Revenue	4.5M
Headquarters	9501 Lakeside Blvd, The Woodlands, Texas 77381, United States

Contact Details

Phone: +1 858-218-8670
Website: cellipont.com
LinkedIn: linkedin.com/company/cellipont-bioservices

Key Focus Areas & Initiatives

Cell therapy manufacturing
CAR-T, TCR-T, and NK cell therapies
Analytical development
Process development
Manufacturing from preclinical to commercial stages
CDMO expertise
Program management
FDA and PAI experience
Supply chain management
Tech transfers and validation
Quality control and assurance
Cell banking
Stability testing and gap analysis
Process verification and scale-up
Patient-first approach
Purpose-built facility and innovative technology
Partnerships with biotech organizations
Consulting and business development
Regulatory compliance and GMP manufacturing
Cell therapy safety and product release
Regenerative medicine
Bioprocess automation

Technologies Used

AMP
Akamai CDN Solutions
BASE
CloudFlare Hosting
Cloudflare DNS
Flow
Google Tag Manager
Infoblox DHCP
Microsoft Active Directory Federation Services
Microsoft Office 365
Microsoft Windows Server 2012
Mobile Friendly
Outlook
Remote
Salesforce
Tor
Vimeo
WordPress.org

Affiliated Organizations & Regional Branches

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.

GTM Automation for VC/PE-backed Startups

Every board deck at a VC or PE-backed startup tells the same story: aggressive revenue targets, intense board pressure after funding, and the need to make every dollar of runway count. Headcount alone doesn't fix pipeline math, especially with lean SDR teams. GTM automation (systematically automating target account

B2B Email List Providers Playbook: Build Clean, Compliant Lists That Actually Convert

In B2B sales, your email list is either a growth engine or a money pit. An outdated, irrelevant, or non-compliant database does not just fail to convert, it harms deliverability, wastes rep time, and increases risk across your GTM motion. That is why choosing B2B Email List Providers (and setting